Please assess the completion status of the following clinical trial:

Trial Title: Saizen in Intra-uterine Growth Retardation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Previous inclusion, good compliance and normal completion of GF4001 or GF6283 in the treatment of growth failure in children born with serious IUGR (3-year continuous r-hGH treatment in GF4001 or 2-year continuous or intermittent r-hGH treatment in GF6283).~* Increase in height greater than 0.5 standard deviation (SD) during the first 2 years of r-hGH treatment in GF4001 or after 2 years of continuous or intermittent r-hGH treatment in GF6283.~* A written Informed Consent at the beginning of the pre-study visit must be obtained from the parent(s)/legal guardian(s), with the understanding that consent may be withdrawn by the subject or parents at any time without prejudice to their future medical care. Children able to understand the trial should personally sign and date the written informed consent, too.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known multiple malformation syndrome with severe psychomotor retardation and/or body hemihypertrophy.~* Severe psychomotor retardation.~* Severe congenital malformations.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saizen® (Continuous or intermittent treatment) (Type: EXPERIMENTAL): None
- Saizen® (Observed and then continuous or no treatment) (Type: EXPERIMENTAL): None
- Observation only (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).